The fundamental promise of colorectal cancer screening—that early detection saves lives—faces scrutiny from a landmark Swedish trial challenging decades of medical orthodoxy. Despite widespread recommendations for routine screening starting at age 50, this massive population study reveals screening may not deliver the cancer prevention benefits patients expect during its critical early years.
The SCREESCO trial randomized nearly 280,000 sixty-year-olds to receive either one-time colonoscopy, two rounds of fecal immunochemical testing, or standard care without screening. After nearly five years of follow-up, neither screening method reduced overall colorectal cancer rates compared to no screening. Colonoscopy participants actually developed cancer at a slightly higher rate (108 versus 100 cases per 100,000 person-years), while FIT testing showed modest but statistically insignificant reduction (96 versus 104 cases per 100,000 person-years). Both screening arms did detect more early-stage cancers, suggesting screening identifies tumors that might otherwise remain undiagnosed.
This contradicts smaller, older studies that formed the basis for current screening guidelines, though those trials often compared different screening strategies rather than screening versus no screening. The findings highlight a critical gap between screening's theoretical benefits and real-world outcomes during the diagnostic phase. However, colorectal cancer's slow progression means mortality benefits may emerge with longer follow-up—the trial continues monitoring participants. The results also reflect screening a single age cohort rather than sustained population screening programs. For now, this represents the highest-quality evidence questioning whether current screening protocols deliver promised near-term cancer prevention, potentially reshaping how clinicians counsel patients about screening's immediate versus long-term value.